NatWest Group plc - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 178 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
NatWest Group plc ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2015$753,000
-41.2%
4,5400.0%0.02%0.0%
Q1 2015$1,280,000
+216.0%
4,540
+74.7%
0.02%
+466.7%
Q4 2014$405,0002,5990.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2015
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders